{"id":"tp-59510","type":"article-newspaper","title":"SELLAS Shares Rise More Than 200% After Leukemia Vaccine Meets Trial Goal","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/59510","datePublished":"2026-11-17T14:55:03.000Z","dateModified":"2026-11-17T14:55:03.000Z","language":"en","abstract":"Median survival was 24.0 months for patients receiving galinpepimut-S, compared with 14.7 months for the comparison group.","section":"Investing","references":[]}